{
    "organizations": [],
    "uuid": "735452da1c93caf24414ce59f4077bbad3162d0e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novartis-says-kymriah-receives-sec/brief-novartis-says-kymriah-receives-second-fda-approval-idUSASO00043N",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis says Kymriah receives second FDA approval",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 1 (Reuters) - Novartis AG:\n* KYMRIAHÂ® (TISAGENLECLEUCEL), FIRST-IN-CLASS CAR-T THERAPY FROM NOVARTIS, RECEIVES SECOND FDA APPROVAL TO TREAT APPROPRIATE R/R PATIENTS WITH LARGE B-CELL LYMPHOMA\n* US FOOD AND DRUG ADMINISTRATION APPROVED KYMRIAH SUSPENSION FOR INTRAVENOUS INFUSION FOR ITS SECOND INDICATION\n* KYMRIAH DEMONSTRATED OVERALL RESPONSE RATE OF 50%, WITH MEDIAN DURATION OF RESPONSE NOT YET REACHED AT TIME OF DATA CUT-OFF\n* KYMRIAH IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-02T04:33:00.000+03:00",
    "crawled": "2018-05-02T07:18:27.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "novartis",
        "ag",
        "tisagenlecleucel",
        "therapy",
        "novartis",
        "receives",
        "second",
        "fda",
        "approval",
        "treat",
        "appropriate",
        "patient",
        "large",
        "lymphoma",
        "u",
        "food",
        "drug",
        "administration",
        "approved",
        "kymriah",
        "suspension",
        "intravenous",
        "infusion",
        "second",
        "indication",
        "kymriah",
        "demonstrated",
        "overall",
        "response",
        "rate",
        "median",
        "duration",
        "response",
        "yet",
        "reached",
        "time",
        "data",
        "kymriah",
        "indicated",
        "treatment",
        "patient",
        "primary",
        "central",
        "nervous",
        "system",
        "lymphoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}